Contineum Therapeutics, Inc. (CTNM) has 14 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 1 sales totalling $628K. Most recent filing: Sept. 8, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 8, 2026 | Stengone Carmine N. CEO and President | $38,617 | 7,500 | 0% | Yes | |
|
|
||||||
| Aug. 3, 2026 | Stengone Carmine N. CEO and President | $37,504 | 7,500 | 0% | Yes | |
|
|
||||||
| July 10, 2026 filed July 8, 2026 | Lorrain Daniel S. Chief Scientific Officer | — | 0 | 0% | Yes | |
|
|
||||||
| July 8, 2026 | Stengone Carmine N. CEO and President | $37,475 | 7,500 | 0% | Yes | |
|
|
||||||
| July 2, 2026 filed June 30, 2026 | Lorrain Daniel S. Chief Scientific Officer | −$66,688 | 103,197 | −11% | Yes | |
|
|
||||||
Showing the 5 most recent of 14 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free